Payment overview · 2025
General Payments
$34,341.17
85 reported records · 21 companies
Healthcare provider profile · identity verified
Gavin Fleming Brown, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CANTON, GA · NPI 1710164975
Verified facts
What the public records show
CMS Open Payments records show Gavin Fleming Brown, M.D. received $34,341.17 in general payments during 2025 across 85 reported records.
Alexion Pharmaceuticals, Inc. accounted for 59.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Rystiggo, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ubrelvy by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART as an associated drug or biological on 6851 records involving 2825 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vyvgart by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Soliris by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Rytary by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Privigen by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rystiggo as an associated drug or biological on 11914 records involving 4077 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rystiggo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20,331.10 | 59.2% | 11 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $5,811.25 | 16.9% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $4,644.44 | 13.5% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $2,319.00 | 6.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $289.30 | 0.8% | 21 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $157.54 | 0.5% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $138.53 | 0.4% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $121.43 | 0.3% | 5 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $99.50 | 0.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.53 | 0.2% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $64.86 | 0.2% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $33.19 | 0.1% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.93 | 0.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.58 | 0.1% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $29.31 | 0.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.19 | 0.1% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $28.80 | 0.1% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $28.62 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $28.24 | 0.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.91 | 0.1% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $17.92 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,827.50 | 15 |
| Consulting Fee | $7,120.00 | 2 |
| Food and Beverage | $1,560.64 | 65 |
| Travel and Lodging | $698.90 | 1 |
| Education | $134.13 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $10,041.10 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $4,644.44 | 6 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $3,678.90 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $2,132.35 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $224.80 | 14 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $157.54 | 6 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $138.53 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $136.27 | 14 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $121.43 | 5 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $71.63 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $71.63 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.52 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $68.52 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $64.86 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $47.93 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $33.19 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $32.93 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $31.58 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $29.31 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $29.19 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $28.24 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rystiggo rystiggo |
2025 | Rystiggo | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART open payments reported associated product |
CMS Open Payments — General Payments 6851 supporting records · 2825 recipient NPIs · example record 1240416066 |
Vyvgart · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Rystiggo open payments reported associated product |
CMS Open Payments — General Payments 11914 supporting records · 4077 recipient NPIs · example record 1224348577 |
Rystiggo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 358 | 91 |
| Gabapentin | Gabapentin | 312 | 93 |
| Memantine Hcl | Memantine Hcl | 282 | 62 |
| Donepezil Hcl | Donepezil Hcl | 187 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 41 |
| Levetiracetam | Levetiracetam | 131 | 33 |
| Prednisone | Prednisone | 116 | 54 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 116 | 34 |
| Lamotrigine | Lamotrigine | 107 | 27 |
| Sertraline Hcl | Sertraline Hcl | 104 | 26 |
| Clonazepam | Clonazepam | 92 | 23 |
| Baclofen | Baclofen | 87 | 21 |
| Topiramate | Topiramate | 72 | 22 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 71 | suppressed |
| Pregabalin | Pregabalin | 71 | 24 |
| Rytary | Carbidopa/Levodopa | 69 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 30 |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 18 |
| Lacosamide | Lacosamide | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 14 |
| Aimovig Autoinjector | Erenumab-Aooe | 48 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 13 |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 42 | 12 |
| Trazodone Hcl | Trazodone Hcl | 40 | 15 |
| Ubrelvy | Ubrogepant | 40 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 39 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 34 | suppressed |
| Azathioprine | Azathioprine | 32 | suppressed |
| Soliris | Eculizumab | 32 | suppressed |
| Keppra | Levetiracetam | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Copaxone | Glatiramer Acetate | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 26 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Alprazolam | Alprazolam | 23 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Riluzole | Riluzole | 22 | suppressed |
| Lamotrigine Er | Lamotrigine | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Vimpat | Lacosamide | 17 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Vyvgart | Efgartigimod Alfa-Fcab | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 14 | suppressed |
| Rystiggo | Rozanolixizumab-Noli | 14 | suppressed |
| Gocovri | Amantadine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34,341.17 · 85 records | Alexion Pharmaceuticals, Inc. | AMYVID, BOTOX, BRIUMVI, CREXONT, Exablate, General - Pain Management, Hizentra, KESIMPTA, KISUNLA, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, QULIPTA, REXULTI, Rystiggo, SPINRAZA, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA, Zilbrysq | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error